Strata Critical Medical, Inc. (SRTA) - Form 8-K Summary
Business Context and Reporting Period
Date: September 16, 2025
Company: Strata Critical Medical, Inc.
Event: Completion of the acquisition of Keystone Perfusion Services, LLC ("Keystone"), an organ recovery and normothermic regional perfusion service provider. The transaction closed on September 16, 2025, via a wholly-owned subsidiary, Strata Critical, Inc.
Key Financial Metrics and Transaction Terms
- Base Purchase Price: $124 million (subject to adjustment).
- Payment Structure: 80% cash and 20% Company common stock.
- Contingent Consideration: Up to $23 million payable over 12, 24, and 36 months based on financial performance targets.
- EBITDA Adjustments:
- Downward adjustment up to $12.4 million if 2025 adjusted EBITDA is below $13,348,402.
- Upward adjustment up to $12.4 million if 2025 adjusted EBITDA exceeds $14,753,497.
- Equity Issuance: 3,434,607 shares of Common Stock issued at closing (approx. 12% of the base purchase price).
- Financial Statements: Pro forma financial information will be filed within 71 days of this report.
Material Changes
The Company has expanded its operations into the organ recovery and normothermic regional perfusion sector. This represents a strategic shift or expansion from its existing critical medical transport services. The filing notes a recent divestiture of the Company's passenger business, which may impact liquidity and operational focus.
Guidance, Outlook, and Risks
Management Commentary: The acquisition is expected to provide anticipated benefits and synergies, though specific financial guidance for the combined entity is not detailed in this filing. The Company expects to realize efficiencies from the integration of Keystone.
Risks and Contingencies:
- Integration Risk: Failure to realize anticipated efficiencies or benefits from the Keystone acquisition.
- Liquidity: Continued incurrence of significant losses and the need to access additional funding.
- Operational: Reliance on third-party operators, aircraft availability, and regulatory changes in the transplant industry.
- Financial: Fluctuating financial results and potential downward adjustments to the purchase price based on EBITDA performance.
- Legal: The Company obtained representation and warranty insurance as its sole recourse for breaches, limiting direct liability exposure post-closing.
Investor Verification Checklist
- Verify the exact cash outflow at closing versus the $124 million base price after transaction expenses.
- Review the upcoming pro forma financial statements (due within 71 days) to assess the impact on debt and liquidity.
- Monitor the 2025 adjusted EBITDA performance of Keystone to determine if the purchase price will be adjusted up or down by up to $12.4 million.
- Assess the dilution impact of the 3,434,607 shares issued and potential future issuances for contingent consideration.
- Confirm the status of the divested passenger business and any remaining liabilities associated with it.